



## **Unilife Appoints Dr. Richard Beckman as Chief Medical Officer**

YORK, Pa., April 9, 2015 -- Unilife Corporation (NASDAQ: UNIS and ASX: UNS), a developer, manufacturer and supplier of injectable drug delivery systems, today announced the appointment of Richard L. Beckman, M.D. to the position of Senior Vice President and Chief Medical Officer. Dr. Beckman will also serve as the General Manager of Unilife's Ocular Delivery Systems business unit.

Dr. Beckman is a board certified ophthalmologist with thirteen years of clinical practice experience and more than twenty years of corporate executive and consultancy experience with a number of global pharmaceutical, biotech, and medical device companies.

Prior to joining Unilife, Dr. Beckman held the position of Chief Medical Officer at Ophthotech Pharmaceuticals, Inc. He also held various leadership roles with Neurotech Pharmaceuticals, Alcon Laboratories, Lux Pharmaceuticals, Becton Dickinson, and Allergan Pharmaceuticals. Dr. Beckman received his medical degree from the University of Michigan, and practiced as a glaucoma specialist for ten years in private practice and three years in academic practice at North Shore University Hospital-Cornell University Medical College, following a Glaucoma Fellowship at Harvard University.

Mr. Alan Shortall, Chairman and CEO of Unilife, said: "Dr. Beckman is a skilled physician who has extensive experience in drug and drug delivery device development. With his medical, technical, and scientific expertise as well as broad industry relationships, Dr. Beckman is an excellent addition to our leadership team and customer-centric business focus."

Dr. Beckman said: "There are many unmet and emerging needs in the delivery of injectable drug therapies. Unilife's portfolio of drug delivery systems has significant potential to enable or enhance patient care across a range of therapeutic areas. I look forward to working with our pharmaceutical customers as they seek to enhance and differentiate their drug therapies."

### **About Unilife Corporation**

Unilife Corporation (NASDAQ:UNIS / ASX: UNS) is a U.S. based developer, manufacturer and commercial supplier of injectable drug delivery systems. Unilife's broad portfolio of proprietary technologies includes prefilled syringes with automatic needle retraction, drug reconstitution delivery systems, auto-injectors, wearable injectors, ocular delivery systems and novel systems. Each of these innovative and highly differentiated platforms can be customized to address specific customer, drug and patient requirements. Unilife's global headquarters and state-of-the-art manufacturing facilities are located in York, PA. For more information, please visit [www.unilife.com](http://www.unilife.com) or download the Unilife IRapp on your iPhone, iPad or Android device.

### **Forward-Looking Statements**

This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because

### **Unilife Corporation**

250 Cross Farm Lane, York, PA 17406    **T** + 1 717 384 3400    **F** + 717 384 3401    **E** [info@unilife.com](mailto:info@unilife.com)    **W** [www.unilife.com](http://www.unilife.com)



such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission.

UNIS-G

***Investor / PR Contacts (US):***

Todd Fromer / Garth Russell  
KCSA Strategic Communications  
P: + 1 212-682-6300

***Analyst Enquiries***

Lynn Piper  
Westwicke Partners  
P: + 1 415-513-1281

***Investor Contacts (Australia)***

Jeff Carter  
Unilife Corporation  
P: + 61 2 8346 6500

**Unilife Corporation**

250 Cross Farm Lane, York, PA 17406   **T** + 1 717 384 3400   **F** + 717 384 3401   **E** [info@unilife.com](mailto:info@unilife.com)   **W** [www.unilife.com](http://www.unilife.com)